Canaccord downgraded Arcellx (ACLX) to Hold from Buy with a price target of $115, down from $130, after Gilead (GILD) announced it is acquiring the company for $115 per share and a continent value right of $5 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Arcellx downgraded to Equal Weight from Overweight at Wells Fargo
- Arcellx downgraded to Neutral from Outperform at Baird
- Arcellx downgraded to Hold from Buy at Truist
- M&A News: Arcellx Stock (ACLX) Booms 70% after Gilead Buys Cancer-Fighting Biotech for $7.8B
- Gilead to acquire Arcellx for $115 per share in cash at closing, or $7.8B